Abstract:OBJECTIVE:To evaluate the use of a new reduced intensity of BuCy conditioning regimen for the treatment of malignant hematologic diseases in aged or intolerable patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) from the siblings.METHODS:Twelve patients with acute lymphoblastic leukemia (ALL, n = 4), acute myelogenous leukemia (AML-M(2), n = 2), chronic myelogenous leukemia (CML, n = 4), and myelodysplastic syndromes-refractory anemia with excess blasts (MDS-RAEB, n = 2) were intolerant of conventional myeloablative therapy because of age (older than 50 years) or having severe concurrent diseases. The median age was 49 years (range 42-64 years). Seven were males and five females. Two of the 12 patients were HLA one antigen-mismatched and the rest HLA identical with their donors. The low dosage conditioning regimen consisted of busulfan (2 mg.kg(-1).d(-1) for 3 days), Ara-C (2 g.m(-2).d(-1) for 1 or 2 times), cyclophosphamide (1.0 g.m(-2).d(-1) for 2 days) and anti-T-lymphocyte globulin (ATG 2.5 mg.kg(-1).d(-1) for 4 days, -5 - -2 day). Granulocyte colony-stimulating factor mobilized bone marrow and peripheral blood stem cells (PBSC) were harvested (1 patient using PBSC alone). All patients received cyclosporin A, short-term MTX and mycophenolate mofetil (MMF) for prophylaxis of acute graft-versus-host disease (aGVHD). DNA short tandem repeat (STR) sequence analysis, cytogenetics and molecular-biologic technique were used to analyze chimerism.RESULTS:All the patients were well tolerated the regimen, with no severe regimen related toxicity. In all the 12 patients, absolute neutrophil count > or = 0.5 x10(9)/L was achieved in 11 to 17 (median 15) days and platelet count > 20 x 10(9)/L in 10 to 23 (median 15) days after transplantation. Complete chimerism was achieved in 11 patients and 1 patient was in mixed chimerism at one month after HSCT. With a median follow-up of 14.5 (4.0-24.0) months, 7 of the 12 patients (58.0%) were alive and 5 (42.0%) of the 7 were disease-free. The probabilities of OS and DFS at 12 months were 75.0% and 48.1%. Five patients (41.6%) had aGVHD and four had local chronic GVHD with a cumulative probability of chronic GVHD of 41.5%.CONCLUSION:This reduced intensity conditioning regimen is well tolerated and safe for HSCT in the older patients or patients with severe concurrent medical conditions and can achieve full chimerism and long-term disease-free survival.

Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia

Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome

[Study on Unrelated Donor Allogeneic Bone Marrow Transplantation with Bu-CY2 Conditioning Regimen for Myelodysplastic Syndrome].

Mixed Chimaerism is Associated with Poorer Long-Term Failure-Free Survival among Aplastic Anaemia Patients Receiving HLA-matched Donor Transplantation

Unmanipulated Haploidentical Haematopoietic Cell Transplantation with Radiation-Free Conditioning in Fanconi Anaemia: A Retrospective Analysis from the Chinese Blood and Marrow Transplantation Registry Group

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

The Incidence, Clinical Outcome, and Protective Factors of Mixed Chimerism Following Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

Unmanipulated Haploidentical Transplantation Conditioning with Busulfan, Cyclophosphamide and Anti-Thymoglobulin for Adult Severe Aplastic Anaemia

[Reduced Intensity of BuCy Conditioning Regimen for Transplantation in the Treatment of Malignant Hematologic Diseases].

Incidence and Predictors of Severe Cardiotoxicity in Patients with Severe Aplastic Anaemia after Haploidentical Haematopoietic Stem Cell Transplantation

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA

Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study

Haplo-Identical Transplantation for Acquired Severe Aplastic Anaemia in A Multicentre Prospective Study

The Impact of Pretransplant Serum Ferritin on Haploidentical Hematopoietic Stem Cell Transplant for Acquired Severe Aplastic Anemia in Children and Adolescents

Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia

Who is the Best Haploidentical Donor for Acquired Severe Aplastic Anemia? Experience from a Multicenter Study

Combined Transplantation of G-CSF Primed Allogeneic Bone Marrow Cells and Peripheral Blood Stem Cells in Treatment of Severe Aplastic Anemia

Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China

Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia

A Modified Conditioning Regimen Based on Low‐dose Cyclophosphamide and Fludarabine for Haploidentical Hematopoietic Stem Cell Transplant in Severe Aplastic Anemia Patients at Risk of Severe Cardiotoxicity